Hirosaki University Hospital ( Site 1501)

Hirosaki, Aomori 036-8563

0 studies enrolling now · 1 studies all time

What they study most

Bladder Cancer

Studies at this site

• Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) — Running, not enrolling